• NIH Office of AIDS Research (OAR) Training Fellowship Award, 2018
• Young Scientist Award- ICIPMBS-2018

Brief about the work of scientist

I am working on cellular factors associated with COVID-19, HIV-associated neurological disease (HAND), HIV-associated lipodystrophy, TDF and TAF -related renal dysfunction and to address the pathogenesis and find out the predictor for severity. I am also involved in CVDs, Prostate cancer to find out the Genetic predictor or Biomarker for drug response to avoid drug- induced toxicity or resistance. I am focusing on issues like, NNRTIs, NRTIs drug-induced toxicity in patients with HIV infection, TDF-related renal dysfunction, Antithrombotic drugs (Clopidogrel, Warfarin, and Acitrom) induced thromboembolic events in patients with cardiac diseases, Docetaxel- induced resistance or toxicity in patients with prostate cancer, Cisplatin-induced resistance or toxicity in patients with cervical cancer and HIV vulnerability and disease progression, HIV-associated Neurocognitive Disorder  (HAND), and metabolic complication like HIV-associated lipodystrophy and now Coronavirus infection using PCR, Sequencing and Micro array.
I look at the genetic and epigenetic variations of drug metabolizing enzymes, transporters and receptor genes in drug responders or drug -induced adverse reactions and non-responders. Likewise, I look at the role of host genes (AIDS Restriction factors- APOBEC, TRIM5α, BST2, Cytokines-MMPs, Apo family of lipoprotein, Lipid Metabolizing Enzyme and Transporter genes etc) with HIV vulnerability and disease progression, HIV comorbidity like HAND and metabolic complication like HIV-associated lipodystrophy. .
Additionally, my lab is involved in routine activities like CYP2B6 genotyping test to know the status of drug metabolizers for Efavirenz regimen (drugs involved with 8-10% Hepatotoxicity, 25-70% Neuropsychiatric toxicity), which are done upon request from the clinician. Likewise, it also includes HLAB57:01 allele testing to know the presence of 01 allele. 01 allele is associated with Abacavir (ABC) - induced hypersensitivity.

Work Experience

Number of publications

 Published Papers: 60, Book chapter: 2, Sequence Submitted: 1

List of publications

1. Shyamveer, Khan AA, Singh H. Effect of genetic variations in drug transporters, metabolizing enzyme and regulatory genes on the development of HIV-associated lipodystrophy. J Gene Med. 2023 Mar 2:e3493. (IF: 4.152)
2. Singh H, Dhotre K, Mahajan SD. Role of APOC3 3238C/G polymorphism in HIV-associated neurocognitive disorder. Microb Pathog. 2023 Apr 10;179:106107. (IF: 3.738).
3. Singh H, Jori C, Shyamveer, Mahajan SD, Aalinkeel R, Kaliyappan K, Schwartz S A. MTP -493G/T, ABCG2 34G/A polymorphisms, its expression in HIV associated lipodystrophy patients. Frontiers in Cardiovascular Medicine- Lipids in Cardiovascular Disease: 30 May 2023, Volume 10-2023(IF:6.05)
4. HariOm Singh, Dharmesh Samani, Supriya D Mahajan. ABCB1 polymorphism in HIV-infected individuals taking anti-retroviral drugs. Frontiers in phaarmacology (IF: 5.5.05).
5. Namdev G, Choudhari R, Shyamveer, Khan AA, Singh H #. Impact of inflammatory cytokine and adipokine gene variations in development of HIV-associated Lipodystrophy. J Gene Med. 2023 Apr 26:e3512. (IF: 4.152)
6. Singh H, Dhotre K. Role of MMP-13-77A/G polymorphism in HIV-associated neurocognitive disorders patients. Microb Pathog. 2022 Aug 30:105740. (IF: 3.738).
7. Singh H, Samani D. TLR3 polymorphisms in HIV infected individuals naïve to ART. Curr HIV Res. 2022 Sep 8. doi: 10.2174/1570162X20666220908105434. (IF:1.581)
8. Pathak P, Kumar V, Khalilullah H, Grishina M, Singh H, Verma A. Debelalactone Prevents Hepatic Cancer via Diminishing the Inflammatory Response and Oxidative Stress on Male Wistar Rats. Molecules. 2022 Jul 14;27(14):4499 (IF:4.148)
9. Yadav E, Yadav P, Khan MMU, Singh H, Verma A. Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction. Front Pharmacol. 2022 Sep 16;13:922232. (IF:5.81). (Citation:2)
10. Hari Om Singh, Vivek Guptaand Amita Singh. Genetic Variations of V3 and C3 regions in gp120 protein of HIV-1 env gene. J Dement 2022, Vol 6(1): 116 (IF:0.05)
11. Singh H, Jakhar K, Nema V, Krishnaraj A, Choudhari R. Effect of miRNAs, Proinflammatory Cytokines and ACE2 in COVID-19 Pathophysiology. Coronaviruses, 2021, 2,1-0 (IF:0.81)
12. Singh H, Samani D, Jadhav S. KDR polymorphism (1192G/A, 1719A/T) and modulation of ARV drug-induced hepatotoxicity. Microb Pathog. 2021 Dec;161(Pt A):105243. (IF: 3.738) (Citation:1)
13. Maan HS, Chaurasia D, Kapoor G, Dave L, Siddiqui A, Pal S, Singh HO, Biswas D, Chowdhary R. Intestinal viral infections of nSARS-CoV2 in the Indian community: Risk of virus spread in India. J Med Virol. 2022 Apr;94(4):1315-1329. (IF: 20.693)
14. Singh H, Jadhav S, Arif Khan A, Aggarwal SK, Choudhari R, Verma S, Aggarwal S, Gupta V, Singh A, Nain S, Maan HS. APOBEC3, TRIM5α, and BST2 polymorphisms in healthy individuals of various populations with special references to its impact on HIV transmission. Microb Pathog. 2022 Jan;162:105326. (IF:3.738) (Citation:2)
15. Sumitra Nain, HariOm Singh, 1, 3, 4 -thiadiazole scaffold: As Anti-Microbial Agents.  Pharmaceutical chemistry journal 2021 (IF:0.868)
16. Singh H#, Jadhav S, Chauware V. Impact of MBL-2 coding region polymorphism on modulation of HAND and HIV-1 acquisition. Microb Pathog. 2021 Sep 1;105163. (IF: 3.738) (Citation:1)
17. Arif Khan, Tashfeen, Muhammad Bilal, Singh H. Microbiota, probiotics and respiratory infections: the three musketeers can tip off potential management of COVID-19". Am J Transl Res 2021;13(10):10977-10993 (IF: 4.06) (Citation:6)
18. Khan AA, Sirsat AT, Singh H#, Cash P. Microbiota and cancer: current understanding and mechanistic implications. Clin Transl Oncol. 2021 Aug 13:1-10.(IF:3.405) (Citation:8)
19. Singh H#, Singh A, Khan AA, Gupta V. Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease. Microb Pathog. 2021 Sep; 158:105023. (IF: 3.738). (Citation:21)
20. Singh H#, Chauware V, Jakhar K. Comparative Occurrence of TLR3 and TLR7 Polymorphisms among healthy individual of various population. Current Pharmacogenomics and Personalized Medicine. Volume 18, Issue 1, 2021 (IF: 1.14)
21. Singh H#,  Lata Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV infection. Current Pharmacogenomics and Personalized Medicine. 2021, DOI: 10.2174/1875692118666210421104202 (IF: 1.14)
22. Singh H#, Choudhari R. Role of Host Genetic Factors in Patients with Astrocytomas. Biotechnol Biomater 2021, 2:1 (IF: 1.75)
23. Singh H#, Choudhari R. Novel Drug Delivery Formulations of Herbal Bioactive Molecules. Indian Journal of Novel Drug Delivery 13(1), Jan-Mar, 2021, 10-17 (IF:0.125)
24. Singh H#, Choudhari R, Nema V, Khan AA. ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. Microb Pathog. 2021 Jan; 150:104621. (IF: 3.738) (Citation:69)
25. Singh H#, Lata S, Choudhari R, Dhole T.N. Prevalence of ABCC3 1767G/A polymorphism among patients with antiretroviral -associated hepatotoxicity. Mol Genet Genomic Med. 2020;00:e1124 (IF: 2.473) ) (Citation:1)
26. Singh H, Samani D, Aggarwal S. TLR7 Polymorphism (rs179008 and rs179009) in HIV-Infected Individual Naïve to ART. Mediators Inflamm. 2020 May 20;2020:6702169. (IF: 4.711) (Citation:4)
27. Singh H#, Nain S, Krishnaraj A, Lata S, Dhole TN. Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. 2019 May 25; 698:41-49. (IF: 3.68) (Citation:4)
28. Singh H, Jadhav S, Samani D, Nain S. Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder. Mediators Inflamm. 2019 May 28;2019:8278095. (IF: 4.711)
29. Singh HO, Maan HS, Dhole TN. Gene Silencing: A Novel Approach and Suppression of HIV-1 Gene. J Mol Genet Med 2019 April 22: 13: 420 (IF:0. 0)
30. Singh H#, Lata S, Dhole TN, Gangakhedkar RR. Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity. Mol Genet Genomic Med. 2019 Apr;7(4):e00598 (IF: 2.473) (Citation:4)
31. Singh HO, Jadhav S, Samani D, Dhole TN. Polymorphisms in miRNAs Gene (146a, 149, 196a) and Susceptibility to ARV-associated Hepatotoxicity. Curr Genomics. 2019 Feb;20(2):134-150. (IF:2.236)
32. Singh H, Samani D, Nain S, Dhole TN. Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity. Microb Pathog. 2019 Aug;133:103544. (IF: 3.738) (Citation:4)
33. Singh H#, Nambiar N, Samani D, Gangakhedkar RR. Occurrence of Interleukin-2 (330 G/T) Promoter Polymorphism in ARV associated hepatotoxicity. Curr Mol Med. 2019 Apr 10. doi: 10.2174/1566524019666190411093451. (IF: 2.222)
34. Singh H#, Gangakhedkar RR. Occurrence of APOBEC3G variations in West Indian HIV patients. Microb Pathog. 2018 Jun 2; 121:325-330. (IF:3. 738) (Citation:4)
35. Singh H#, Lata S, Gangakhedkar RR. Prevalence of CYP2D6*4 1934G/A Polymorphism in Western Indian HIV patients. APMIS. 2018 Nov;126(11):842-851(IF:3.26) (Citation:1)
36. Singh H#, Samani D, Nema V, Ghate M.V, and Gangakhedkar R,R. IL-1RN and IL-1β Polymorphism and ARV-Associated Hepatotoxicity. Mediators of Inflammation. 2018 Apr 8;2018:4398150 (IF: 4.711) (Citation:9)
37. Singh H#, Samani D, Nambiar N, Ghate MV, Gangakhedkar RR. Effect of matrix metalloproteinase-21 (572C/T) polymorphism on HIV-associated neurocognitive disorder. 2018 Apr; 126(4):329-336. (IF: 3.26) (Citation:3)
38. Singh H#, Samani D, Nambiar N, Ghate MV, Gangakhedkar RR. Prevalence of MMP-8 gene polymorphisms in HIV-infected individuals and its association with HIV-associated neurocognitive disorder. 2018 Mar 10;646:83-90 (IF: 3.68) (Citation:11)
39. Singh H# and Nain S. Matrix Metalloproteinases Enzyme and Risk for HIV-Associated Neurocognitive Disorders. Austin Journal of HIV/AIDS Research. January 30, 2018 (IF:0.0)
40. Singh H#, Samani D, Ghate MV, Gangakhedkar RR. Impact of cellular restriction gene (TRIM5α, BST-2) polymorphisms on the acquisition of HIV-1 and disease progression. J Gene Med. 2018 Feb; 20(2-3):e3004. (IF: 4.152) (Citation:10)
41. Singh H#, Lata S, Nema V, Samani D, Ghate M, Gangakhedkar RR. CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity. 2017 Jun; 125(6):523-535. (IF: 3.26) (Citation:5)
42. Singh H#, Marathe S D, Nain S, Samani D, Nema V, Ghate M V, Gangakhedkar R . Promoter polymorphism MMP-1 (-1607 2G/1G) and MMP-3 (-1612 5A/6A) in development of HAND and modulation of pathogenesis of HAND. J Biosci. 2017 September, 42, 481–490 (IF: 1. 826) (Citation:5)
43. Singh HO#, Lata S, Angadi M, Bapat S, Pawar J, Nema V, Ghate MV, Sahay S, Gangakhedkar RR. Impact of GSTM1, GSTT1 and GSTP1 gene polymorphism and risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulation. Pharmacogenomics J. 2017 Jan; 17(1):53-60. (IF:3.55) (Citation:19)
44. Vijay Nema, Hari Om Singh. Host Pharmacogenomics: to be Remembered while Planning a Cure for HIV. BAOJ Hiv 2017 3:1 (IF:0.0)
45. Singh H#, Marathe S, D, Nain S, Nema V, Ghate M. V, Gangakhedkar R, R. Impact of variants of MMP-7(-181A>G) gene in susceptibility to development of HAND and its severity. APMIS. 2016 Nov;124(11):966-972 (IF: 3.26) (Citation:4)
46. HariOm Singh#, Shruti D Marathe, Vijay Nema, Manisha Ghate, Raman R.Gangakhedkar. Genetic variation of MMP-2 & MMP-9 polymorphism in susceptibility to development of HAND and its severity. J Gene Med. 2016 Sep; 18(9):250-7. (IF: 4.152) (Citation:4)
47. HariOm Singh#, Shruti D Marathe, Sumitra Nain, Vijay Nema, Manisha V Ghate, Raman.R.Gangakhedkar. APOBEC3B deletion impacts on susceptibility to acquire HIV-1 and its advancement among Individuals in Western India. 2016 Oct;124(10):881-7 (IF: 3.26) (Citation:9)
48. HariOm Singh#, Shruti Marathe, Sumitra Nain, Mansa Angadi, Shradha Bapat, Jyoti Pawar,Vijay Nema, Manisha Ghate, Seema Sahay, R.R.Gangakhedkar .Coding region variant 186H/R in Exon 4 of APOBEC3G among individuals of Western India. 2016 May;124(5):401-5 (IF: 3.26)
49. Supriya D. Mahajan*,Asmita Gaekwad, Jyoti Pawar, Srikanth Tripathy, Manisha Ghate, Jayanta Bhattacharya, HariOm Singh, Stanley A. Schwartz, Ramesh Paranjape and Raman Gangakhedkar. Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism. Curr HIV Res. 2015; 13(2):98-108. (IF:1.581) (Citation:5)
50. Sumitra Nain,* Anu Sharma, Hariom Singh, Sarvesh Paliwal. Recent Advances in use of Semicarbazones as Anticonvulsant Agents: A Review. Biomed. Ther. Sci. 2015, 2(1), 1-7 (IF: 2.0) (Citation:8)
51. Hari Om Singh#, Amita Singh, TN Dhole and Sumitra Nain. Effect of Ormeloxifene for Management of Dysfunctional Uterine Bleeding. Biochem Physiol 2015, 4:3
52. HariOm Singh#, Amita Singh, TN Dhole and Sumitra Nain. Factor associated to Bacterial Vaginosis in Nonpregnant women of North Indian population. J Biotechnol Biomater 2015, 5:3
53. Hari OS#, Sonali G and Sumitra N. Awareness and Trends of Blood Cholesterol and Susceptibility to Develop Heart Disease. Adv Genet Eng 2015, 4:3
54. Gangwar R, Mittal B. Srivastava Shuti, Singh H, Mittal R Genetic Variants of DNA Repair Gene XPC Modulating Susceptibility to Cervical Cancer in North India. Onco Res 2010; 18:1-100. (IF:4.
    83) (Citation:8)
55. Singh H, Jain M, Mittal B. TGF-β1 (-509C/T) Gene Polymorphisms and Susceptibility to Cervical Cancer.Onco Res. 2009; 18(1):41-5. (IF:4.
    83) (Citation:8)
56. Singh H, Sachan R, Devi S, Pandey S N, Mittal B. Association of GSTM1, GSTT1 and GSTM3 gene polymorphisms and susceptibility to cervical cancer in North Indian population. Am J Obstet Gynecol. 2008; 198:303-6. (IF: 9.491) (Citation:102)
57. Singh H, Sachan R, Geol H, Mittal B. Genetic Variations in Interleukin-1 receptor antagonist and Interleukin-1β genes and cervical cancer. British J. Obstetrics and Gynecology 2008; 115:633–638. (IF:7.331) (Citation:27)
58. Singh H, Sachan R, Jain M, Mittal B. CCR5-Δ32 Polymorphism and Susceptibility to Cervical Cancer: Association with Early Stage of Cervical Cancer. Oncol Res. 2008; 17:87-91. (IF:4.
    83) (Citation:35)
59. Singh H, Jain M, Sachan R, Mittal B. TNF-α (-308G/A) and IL-10(-819C/T) Promoter Polymorphisms and Risk of Cervical Cancer. J Gynecological Cancer 2009; 19(7):1190-1194. (IF: 4.661) (Citation: 62)
60. Singh H, Jain M, Mittal B. MMP-7(-181 A/G) Gene Polymorphisms and Risk for Cervical Cancer. Gynecol Oncol. 2008; 110:71-5. (IF:  5.482) (Citation: 49)

Book chapter:2

1. Sumitra Nain, Garima Mathur,Pragati Karana, HariOm Singh. Physical and Chemical Properties of Nanobiomaterials. Pharmaceutical Technology (Nanobiomaterials
   Applications in Drug Delivery) Apple Academic Press. Mar, 2017.
2. HariOm Singh#, Antony Jenitha A, Amita Verma, Anchal Singh. Role of Matrix metalloproteinases (MMPs) and Tissue inhibitor of metalloproteinases (TIMPs) genes in NeuroHIV. Neuropsychiatric complications in HIV. Accepted March 31

Gene sequence

Jagtap,D.D., Gupte,D.S., Thakar,M.R., Singh,H.O., Pandey,S., C,S.K. and Paranjape,R.S. Molecular characterization of tetherin/BST-2 gene promoter in  Indian HIV infected long term non progressors. GenBank-2014